Industry News
Biotechnology Industry News
Immunology biotech Agomab…
Immunology biotech Agomab Therapeutics and eye-focused SpyGlass Pharma have both unveiled their intentions to go public, in the latest sign that the IPO window is reopening in 2026.
Vedanta Biosciences has…
Vedanta Biosciences has “significantly reduced” its headcount to channel its remaining resources to its lead live bacteria cocktail program.
ImmunityBio has reported ongoing…
ImmunityBio has reported ongoing complete responses of up to 15 months in two recipients of its CAR-NK cell therapy, leading the biopharma to talk up the prospects of the off-the-shelf blood cancer treatment.
The leaders of Chugai…
The leaders of Chugai Pharmaceutical are tired of their company not getting its due. At the J.P. Morgan Healthcare Conference in San Francisco, they’re working hard to change that while also seeking out new science
iRegene’s NouvNeu001 earns dual…
iRegene’s NouvNeu001 earns dual FTD/RMAT status, a first for iPSC therapies. Strong Phase I data in PD validates its scalable chemical induction platform.
After last year’s upheaval at…
After last year’s upheaval at the CDC’s Advisory Committee on Immunization Practices, HHS Secretary Robert F. Kennedy, Jr. is not done filling out the panel. The secretary this week added two OB-GYNs to the panel
Ocugen has reported preliminary…
Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may outperform existing treatments from Apellis and Astellas.
Italian pharma Alfasigma has…
Italian pharma Alfasigma has penned a 125 million euros ($145 million) deal for the rights to an injectable form of an investigational HSV encephalitis treatment.
Hopes were high Wednesday for a…
Hopes were high Wednesday for a billion-dollar megadeal—the kind the J.P. Morgan Healthcare Conference is known for—but no major deals ever materialized.
With a White House drug pricing…
With a White House drug pricing deal done and dusted and the threat of tariffs ameliorated, Sanofi is now enjoying more clarity from the federal government than at the same time last year. But several
Caldera has burst onto the scene…
Caldera has burst onto the scene with $112.5 million in combined series A cash the Massachusetts biotech will use to fund development of an inflammatory bowel disease drug licensed from China.
The Novo Nordisk Foundation is…
The Novo Nordisk Foundation is investing 5.5 billion Danish kroner in the BioInnovation Institute to help scale up more homegrown biotechs and deep tech companies.
Still riding the high of last…
Still riding the high of last year’s twice-yearly HIV PrEP approval of lenacapavir as Yeztugo, Gilead Sciences is approaching deal-making from a “position of strength” as a more mature biopharma, CEO Daniel O’Day told journalists
The twisting journey of Pretzel…
The twisting journey of Pretzel Therapeutics’ top brass appears to have come full circle, with the biotech subsuming the very company where some of its senior figures once worked.
The J.P. Morgan Healthcare…
The J.P. Morgan Healthcare Conference is rolling on Tuesday with many more conference-related events on the docket, including the start of Fierce JPM Week. Our reporters and editors are on the ground in San Francisco
Lyra Therapeutics is abandoning…
Lyra Therapeutics is abandoning work on its rhinosinusitis treatment and laying off its remaining employees.
Gary Gibbons, M.D., is retiring as…
Gary Gibbons, M.D., is retiring as National Heart, Lung and Blood Institute director, adding to the extensive churn at the top of the National Institutes of Health. The departure will mean 15 of the NIH’s
SAN FRANCISCO—The deal-hungry…
SAN FRANCISCO—The deal-hungry Danish pharma is largely sticking to its metabolic roots as it seeks out new innovation to bring into its drug development machine.
It’s been a subdued—albeit…
It’s been a subdued—albeit sunny—start to healthcare’s biggest conference in San Francisco. For Takeda's R&D head Andy Plump, M.D., Ph.D., the slower pace of the annual J.P. Morgan Healthcare Conference has been offset by the industry's
AbbVie has made no secret of the…
AbbVie has made no secret of the fact that it's taken an interest in the hotly contested PD-1xVEGF bispecific space. Now, the Big Pharma has paid $650 million to make its ambitions in this arena